Abstract: The invention provides novel coumarin derivatives as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.
Type:
Grant
Filed:
September 20, 2018
Date of Patent:
September 7, 2021
Assignees:
Lead Discovery Center GmbH, Max Planck Gesellschaft zur Förderung der Wissenschften e.V., SOTIO a.s.
Inventors:
Raffaella Di Lucrezia, Tim Bergbrede, Peter Nussbaumer, Uwe Koch, Bert Klebl, Axel Choidas, Anke Unger, Nils-Göran Larsson, Maria Falkenberg-Gustafsson, Claes M. Gustafsson
Abstract: Disclosed are pharmaceutical compositions for inducing an immune response against tumor cells comprising tumor cells which are made apoptotic by treatment with high hydrostatic pressure and dendritic cells, and methods for producing such compositions.
Type:
Grant
Filed:
March 26, 2019
Date of Patent:
February 16, 2021
Assignee:
SOTIO a.s.
Inventors:
Ji{hacek over (r)}ina Bartů{hacek over (n)}ková, Radek {hacek over (S)}pí{hacek over (s)}ek
Abstract: Disclosed are pharmaceutical compositions for inducing an immune response against tumor cells comprising tumor cells which are made apoptotic by treatment with high hydrostatic pressure and dendritic cells, and methods for producing such compositions.
Type:
Grant
Filed:
June 27, 2017
Date of Patent:
February 2, 2021
Assignee:
SOTIO a.s.
Inventors:
Ji{hacek over (r)}ina Bartů{hacek over (n)}ková, Radek {hacek over (S)}pí{hacek over (s)}ek
Abstract: Described herein is a reliable method for preparing a potent vaccine useful for immunotherapy comprising the step of cryopreserving a population of cells undergoing immunogenic cell death, and using such cells to activate dendritic cells for use in immunotherapy. In a specific embodiment, the method comprises cryopreserving cancer cells undergoing cell death, which can be used to prepare a pharmaceutical composition for immunotherapy against cancer.
Abstract: Described herein is a reliable method for preparing a potent vaccine useful for immunotherapy comprising the step of cryopreserving a population of cells undergoing immunogenic cell death, and using such cells to activate dendritic cells for use in immunotherapy. In a specific embodiment, the method comprises cryopreserving cancer cells undergoing cell death, which can be used to prepare a pharmaceutical composition for immunotherapy against cancer.
Abstract: Described herein are methods for the preparation of stable semi-mature tolerogenic dendritic cells and compositions comprising such stable semi-mature tolerogenic dendritic cells. The stable semi-mature tolerogenic dendritic cells described herein and compositions thereof can be used for the establishment of immune tolerance when treating an autoimmune disease, graft rejection and/or graft-versus-host disease.
Type:
Grant
Filed:
October 22, 2015
Date of Patent:
June 5, 2018
Assignee:
SOTIO A.S.
Inventors:
Lenka Palová Jelínková, Klára Dáñová, Radek S̆pí{hacek over (s)}ek
Abstract: Described herein is a reliable method for preparing a potent vaccine useful for immunotherapy comprising the step of cryopreserving a population of cells undergoing immunogenic cell death, and using such cells to activate dendritic cells for use in immunotherapy. In a specific embodiment, the method comprises cryopreserving cancer cells undergoing cell death, which can be used to prepare a pharmaceutical composition for immunotherapy against cancer.
Abstract: Described herein is a reliable method for preparing a potent vaccine useful for immunotherapy comprising the step of cryopreserving a population of cells undergoing immunogenic cell death, and using such cells to activate dendritic cells for use in immunotherapy. In a specific embodiment, the method comprises cryopreserving cancer cells undergoing cell death, which can be used to prepare a pharmaceutical composition for immunotherapy against cancer.
Abstract: The present invention relates to an in vitro method for the diagnosis and/or the monitoring and/or predicting the progress of a cancer disease, characterized in that in at least one sample the ratio of Tregs-cells to at least one other group of T cells comprising the group of Th17 cells, Th1 cells and/or Th2 cells is determined.
Abstract: Described herein is a reliable method for preparing a potent vaccine useful for immunotherapy comprising the step of cryopreserving a population of cells undergoing immunogenic cell death, and using such cells to activate dendritic cells for use in immunotherapy. In a specific embodiment, the method comprises cryopreserving cancer cells undergoing cell death, which can be used to prepare a pharmaceutical composition for immunotherapy against cancer.
Abstract: Disclosed are pharmaceutical compositions for inducing an immune response against tumor cells comprising tumor cells which are made apoptotic by treatment with high hydrostatic pressure and dendritic cells, and methods for producing such compositions.
Abstract: Disclosed are pharmaceutical compositions for inducing an immune response against tumor cells comprising tumor cells which are made apoptotic by treatment with high hydrostatic pressure and dendritic cells, and methods for producing such compositions.